View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 17, 2018

Alliance Global to market Biocept liquid biopsy tests

US-based molecular diagnostics company Biocept has signed a provider agreement for Alliance Global to market and distribute its Target Selector liquid biopsy tests in the UAE, certain Middle East countries, North & Sub-Saharan Africa and the South East Asia (MEAA) region.

US-based molecular diagnostics company Biocept has signed a provider agreement for Alliance Global to market and distribute its Target Selector liquid biopsy tests in the UAE, certain Middle East countries, North & Sub-Saharan Africa and the South East Asia (MEAA) region.

Under the agreement, the diagnostics company will carry out all diagnostic testing services in its San Diego-based laboratory, while Alliance Global will be responsible for sales, marketing, distribution and reimbursement.

“In all the tests performed to date, the liquid biopsy technology platform is said to have successfully detected cancer mutations and alterations, allowing disease diagnosis and treatment decisions.”

The Target Selector platform is designed to capture and analyse related molecular markers in circulating tumour cells (CTCs), as well as plasma (ctDNA).

Alliance Global commercial operations group director Nassim-Marie Hambouz said: “Offering Biocept’s novel liquid biopsy tests supports our commitment to bringing innovative biomedical products and services to emerging markets, and this agreement reflects Alliance Global’s focus on the growing clinical genomics sector in the MEAA region.

“A major focus will be to use Biocept’s testing services to support global biopharmaceutical companies in qualifying patients for their targeted therapies.”

In all the tests performed to date, the liquid biopsy technology platform is said to have successfully detected cancer mutations and alterations, allowing disease diagnosis and treatment decisions.

Biocept president and CEO Michael Nall said: “We are enthusiastic about the opportunities with a capable partner in this important region, and given our strong global intellectual property position, we will continue to be opportunistic in seeking to develop the market for our liquid biopsy solutions internationally.”

Target Selector tests are currently available across 17 countries under eight international agreements signed by the company.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network